The ASPREE Cancer Endpoint Study (ACES), an ancillary study of the ASPirin in the Prevention
of Events in the Elderly (ASPREE) Study, will allow for the examination of the effect of
daily low-dose aspirin (100 mg) compared to placebo, on specific DNA biomarkers and selected
specific incident and recurrent cancer and metastases. The establishment of this ACES biobank
will allow for the exploration of DNA-related molecular mechanisms of aspirin's protective
effect against cancer, cancer associated mortality and metastases, using blood or saliva DNA
specimens, urine, and tumor tissue.
Phase:
Phase 4
Details
Lead Sponsor:
Hennepin Healthcare Research Institute Minneapolis Medical Research Foundation
Collaborators:
Bayer Berman Center for Outcomes and Clinical Research Monash University National Cancer Institute (NCI) National Health and Medical Research Council, Australia National Institute on Aging (NIA)